Glaxo says study isn’t too damaging
From Times Staff and Wire Reports
GlaxoSmithKline’s chief executive said there was an overreaction to a study linking the company’s diabetes drug Avandia to heart attacks and predicted the firm would not be unduly damaged.
Jean-Pierre Garnier told shareholders during the European company’s annual meeting that sales might be affected , but that a careful evaluation of all the evidence should reaffirm the true value of the medicine.
An analysis of dozens of trials, published in the New England Journal of Medicine on Monday, concluded that Avandia increased the risk of heart attack by 43% and cardiac-related death by 64%.
